OBJECTIVE: Levels of CCL18 are elevated in patients with scleroderma lung disease and other fibrotic pulmonary diseases associated with T lymphocyte involvement. We sought to determine whether CCL18 alone can induce pulmonary T lymphocytic infiltration and fibrosis in mouse lungs. METHODS: An adenovirus vector was constructed and used for CCL18 delivery to mouse lungs in vivo. Immunohistochemical, flow cytometric, and enzyme-linked immunosorbent assay analyses were used to assess the resulting changes. RESULTS: Overexpression of CCL18 led to massive perivascular and peribronchial infiltration of T lymphocytes. Although the expression of CCL18 peaked on day 7, the infiltration persisted up to day 64 after infection. The infiltrates were negative for proliferating cell nuclear antigen and TUNEL, suggesting the role of cell trafficking, rather than proliferation and apoptosis, in the infiltration dynamics. Patchy destruction of the alveolar architecture and collagen accumulation in association with the infiltrates were also noticed. These changes were infiltration-dependent, rather than CCL18-dependent, since treatment with antilymphocyte serum completely abrogated the CCL18-induced changes. The infiltrates consisted almost exclusively of T lymphocytes that were minimally activated, with a minimal increase in the expression of CD69 and no changes in the expression of CD25, Fas, FasL, or CD40L. There was no increase in total pulmonary levels of profibrotic cytokines transforming growth factor beta1 (TGFbeta1) or interleukin-13, although active TGFbeta1 was present locally in association with the infiltrates and areas of distorted alveolar architecture. Prestimulation of primary T lymphocytes with CCL18 in vitro caused an up-regulation of TGFbeta1 and collagen production in T lymphocyte/fibroblast cocultures. CONCLUSION: CCL18 promotes selective, long-term pulmonary infiltration of T lymphocytes and infiltration-dependent accumulation of collagen through a TGFbeta1-dependent mechanism.
OBJECTIVE: Levels of CCL18 are elevated in patients with scleroderma lung disease and other fibrotic pulmonary diseases associated with T lymphocyte involvement. We sought to determine whether CCL18 alone can induce pulmonary T lymphocytic infiltration and fibrosis in mouse lungs. METHODS: An adenovirus vector was constructed and used for CCL18 delivery to mouse lungs in vivo. Immunohistochemical, flow cytometric, and enzyme-linked immunosorbent assay analyses were used to assess the resulting changes. RESULTS: Overexpression of CCL18 led to massive perivascular and peribronchial infiltration of T lymphocytes. Although the expression of CCL18 peaked on day 7, the infiltration persisted up to day 64 after infection. The infiltrates were negative for proliferating cell nuclear antigen and TUNEL, suggesting the role of cell trafficking, rather than proliferation and apoptosis, in the infiltration dynamics. Patchy destruction of the alveolar architecture and collagen accumulation in association with the infiltrates were also noticed. These changes were infiltration-dependent, rather than CCL18-dependent, since treatment with antilymphocyte serum completely abrogated the CCL18-induced changes. The infiltrates consisted almost exclusively of T lymphocytes that were minimally activated, with a minimal increase in the expression of CD69 and no changes in the expression of CD25, Fas, FasL, or CD40L. There was no increase in total pulmonary levels of profibrotic cytokines transforming growth factor beta1 (TGFbeta1) or interleukin-13, although active TGFbeta1 was present locally in association with the infiltrates and areas of distorted alveolar architecture. Prestimulation of primary T lymphocytes with CCL18 in vitro caused an up-regulation of TGFbeta1 and collagen production in T lymphocyte/fibroblast cocultures. CONCLUSION:CCL18 promotes selective, long-term pulmonary infiltration of T lymphocytes and infiltration-dependent accumulation of collagen through a TGFbeta1-dependent mechanism.
Authors: Pavel Kopach; Virginia Lockatell; Edward M Pickering; Ronald E Haskell; Richard D Anderson; Jeffrey D Hasday; Nevins W Todd; Irina G Luzina; Sergei P Atamas Journal: J Biol Chem Date: 2014-03-11 Impact factor: 5.157
Authors: Irina G Luzina; Pavel Kopach; Virginia Lockatell; Phillip H Kang; Ashish Nagarsekar; Allen P Burke; Jeffrey D Hasday; Nevins W Todd; Sergei P Atamas Journal: Am J Respir Cell Mol Biol Date: 2013-12 Impact factor: 6.914
Authors: Irina G Luzina; Edward M Pickering; Pavel Kopach; Phillip H Kang; Virginia Lockatell; Nevins W Todd; John C Papadimitriou; Andrew N J McKenzie; Sergei P Atamas Journal: J Immunol Date: 2012-05-25 Impact factor: 5.422
Authors: Irina G Luzina; Virginia Lockatell; Nevins W Todd; Achsah D Keegan; Jeffrey D Hasday; Sergei P Atamas Journal: Immunology Date: 2011-01-10 Impact factor: 7.397
Authors: Irina G Luzina; Achsah D Keegan; Nicola M Heller; Graham A W Rook; Terez Shea-Donohue; Sergei P Atamas Journal: J Leukoc Biol Date: 2012-07-10 Impact factor: 4.962
Authors: Natalia Nacu; Irina G Luzina; Kendrick Highsmith; Virginia Lockatell; Kerill Pochetuhen; Zachary A Cooper; Michael P Gillmeister; Nevins W Todd; Sergei P Atamas Journal: J Immunol Date: 2008-04-01 Impact factor: 5.422
Authors: Irina G Luzina; Nevins W Todd; Natalia Nacu; Virginia Lockatell; Jung Choi; Laura K Hummers; Sergei P Atamas Journal: Arthritis Rheum Date: 2009-05
Authors: Irina G Luzina; Virginia Lockatell; Sang W Hyun; Pavel Kopach; Phillip H Kang; Zahid Noor; Anguo Liu; Erik P Lillehoj; Chunsik Lee; Alba Miranda-Ribera; Nevins W Todd; Simeon E Goldblum; Sergei P Atamas Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-03-18 Impact factor: 5.464
Authors: Kerill Pochetuhen; Irina G Luzina; Virginia Lockatell; Jung Choi; Nevins W Todd; Sergei P Atamas Journal: Am J Pathol Date: 2007-06-14 Impact factor: 4.307